Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
24 mars 2022 06h30 HE
|
Vera Therapeutics
Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim...
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
21 mars 2022 07h30 HE
|
Vera Therapeutics
Management to provide overview of MAU868, its lead asset in the treatment of BK Virus infections in kidney transplant patients BK Virus is a leading cause of transplant loss and transplant-associated...
Vera Therapeutics to Host Business Update Call
17 mars 2022 07h30 HE
|
Vera Therapeutics
BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
01 mars 2022 07h30 HE
|
Vera Therapeutics
BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
14 févr. 2022 16h01 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
10 févr. 2022 08h46 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”) (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
07 févr. 2022 17h24 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
18 janv. 2022 07h30 HE
|
Vera Therapeutics
BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 07h30 HE
|
Vera Therapeutics
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
17 déc. 2021 07h30 HE
|
Vera Therapeutics
Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of...